ESGCT 2025 | Viralgen Aava Platform

Just had a great conversation at #ESGCT2025 with my friend, Anna Dirienzo, Global Director of Marketing and Communications at Viralgen, where she introduced me to Aava – the company’s industry-leading platform for AAV-based gene therapy manufacturing. Anna described both of Aava’s two current forms – Gen 2.0 (Mendi) and Gen 3.0 (Ituri) – and explained how the platform has been instrumental in guiding Viralgen clients to a 100% success rate in IND/IMPD submissions. (And she did it all in just three minutes!)

With a sincere tip of the hat to Anna (and Aava), here's the full, quick interview!